Aldeyra Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $70.0M | $54.5M | $142.8M | $144.4M | $229.8M | $77.9M | $44.4M | $47.4M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $71.8M | $104.1M | $147.8M | $181.0M | $232.8M | $83.1M | $75.2M | $94.8M |
| Property, Plant & Equipment | — | $0 | $5.8K | $19.3K | $32.5K | $59.9K | $148.4K | $235.2K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M | $83.4M | $75.5M | $95.1M |
| Liabilities | ||||||||
| Accounts Payable | $158.5K | $180.5K | $1.3M | $133.6K | $1.0M | $381.6K | $808.3K | $3.1M |
| Total Current Liabilities | $27.8M | $18.6M | $22.3M | $15.4M | $11.8M | $12.4M | $12.9M | $8.5M |
| Long-Term Debt | $0 | $15.0M | $0 | $14.9M | $15.5M | $11.4M | $14.5M | — |
| Total Liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M | $23.8M | $27.4M | $8.5M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-484.0M | $-450.1M | $-394.3M | $-356.7M | $-294.7M | $-236.9M | $-199.4M | $-138.5M |
| Total Stockholders' Equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M | $59.5M | $48.1M | $86.6M |